Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

J. Remon*, L.E.L. Hendriks

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)368-370
Number of pages3
JournalJournal of Thoracic Oncology
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Mar 2021

Keywords

  • HIGH-RISK
  • IMATINIB

Cite this